Preferences for Social Media Vaccination Messaging - Top-Institutions - MDSpire

Preferences for Social Media Vaccination Messaging

  • By

  • Lucía Abascal Miguel

  • Alison B. Comfort

  • Alicia R. Riley

  • Gilberto Lopez

  • Janelli Vallin

  • Anna E. Epperson

  • Nadia Diamond-Smith

  • March 18, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Bloomberg School of Public Health
    Johns Hopkins Bloomberg School of Public Health

    Baltimore, MD

    Key Differentiators

    • Public Health
    • Vaccine Research
    • Health Communication

  • #2

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Epidemiology
    • Health Behavior
    • Digital Health Communication

  • #3

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Vaccine Policy
    • Health Communication

  • #4

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Public Health
    • Immunization Programs
    • Health Communication

  • #5

    University of Michigan School of Public Health
    University of Michigan School of Public Health

    Ann Arbor, MI

    Key Differentiators

    • Health Behavior and Health Education
    • Digital Health
    • Vaccine Hesitancy

Original Source(s)

Preferences for Social Media Vaccination Messaging

  • by Lucía Abascal Miguel, Alison B. Comfort, Alicia R. Riley, Gilberto Lopez, Janelli Vallin, Anna E. Epperson, Nadia Diamond-Smith

  • March 18, 2026

Related Content

Parenteral neonatal priming followed by heterologous mucosal booster favors IgM+ memory B cell induction over systemic plasma cell differentiation

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.